MagnetOs
DeviceMagnetOs will be used at a volume of approximately 1-5 cc's for the TN, CC and ST joints, and up to 10 cc's for the tibiotalar joint.
NCT Number: NCT07225751
This is a phase IV post-marketing study for MagnetOs Putty and MagnetOs Easypack Putty. MagnetOs is a synthetic bone graft extender product that is routinely used by surgeon as treatment for hindfoot and ankle disorders.
In this study, MagnetOs Putty and MagnetOs Easypack Putty will be use according to the latest Instructions For Use, standalone in the foot and ankle.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Steadman Philippon Research Institute, Vail, Colorado, United States
In this study, following a screening period of a maximum of 45 days, approximately 126 patients will receive either MagnetOs Putty/Easypack Putty or autograft in conjunction with rigid hardware (arthrodesis) to treat hindfoot and ankle disorders. They will be randomized (1:1) into one of two treatment groups: standard rigid fixation with MagnetOs Putty/Easypack Putty or local autograft from the calcaneus, distal tibia, or proximal tibia.
They will be followed up at discharge at weeks 2, 6, 12, 24 and 52 post-surgery. The primary endpoint will be analyzed at 24 weeks post-op using CT-scan, and patients will continue follow-up for safety and efficacy for one year post operatively.
In this study, MagnetOs will be applied according to the IFU (Putty) approved in the US, Europe, Middle- East and Australia and Easypack Putty (approved in the US).
The surgical procedures studied in this clinical trial will include rigid hardware fixation and supplemental bone graft/substitute in the following procedures: ankle fusion (tibiotalar), subtalar fusion (talocalcaneal), calcaneocuboid fusion, talonavicular fusion, OR double fusion (any combination of any two of the following: subtalar, talonavicular and calcaneocuboid joints. These procedures will be left to the investigator's discretion.
Radiographs images will be taken at screening, weeks 6, 12, 24 and 52; CT-scans will be taken at weeks 24 and 52 post-op If the patient has a secondary surgical intervention (procedure that adjusts or in any way modifies or removes part of the original implant configuration) at any time after the 6 month visit, the next CT scan will not be necessary. Starting at week 12, all XR images will be weight bearing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion:
Exclusion:
MagnetOs will be used at a volume of approximately 1-5 cc's for the TN, CC and ST joints, and up to 10 cc's for the tibiotalar joint.
In this study, the comparator is autograft and will be used at a volume of approximately 1-5 cc's for the TN, CC and ST joints, and up to 10 cc's for the tibiotalar joint.
Time frame: Week 24 post-op
The primary endpoint is the incidence of fusion at each side by CT analysis as assessed by the independent radiological expert at 24 weeks post-op
Time frame: Week 52
Joint fusion at Week 52 post-surgery assessed by CT-scans determined by an independent radiological expert panel (IREP) in patients undergoing hindfoot or ankle fusions
Time frame: week 12, week 24, week 52 post-surgery
Joint fusion at Week 12, Week 24 and Week 52 post-surgery assessed by plain radiographs determined by an independent radiological expert panel (IREP) in patients undergoing hindfoot or ankle fusions
Time frame: Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery.
Change in Foot Function Index (FFI) from Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery. The score ranging from 0% to 100% indicates the severity of a person's foot issues. A score of 100% indicates worst possible pain, while 0% indicates no pain.
Time frame: Screening, Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery.
Change in Visual Analog Score (VAS) from Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery. 0 no pain and 10 worst pain possible
Time frame: Screening, Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery.
Change in SF-12 from Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery. Where 50 is the average health status for general U.S population. A score above 50 indicates better than average, while a score below 50 suggests below average health.
Contact information is provided by the study sponsor or research team.
Kuros Biosurgery AG
Industry
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions
Acronym: ASTRA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03481725
Ankle Arthrodesis or Arthroplasty, Anterior Cruciate Ligament Reconstruction
San Diego, California, United States
View Trial DetailsNCT00942032
Hindfoot Arthrodesis, Hindfoot Pathologies
Rancho Mirage, California, United States
View Trial DetailsNCT07289620
Ankle Disease, Foot Diseases
Poznan, Poland
View Trial DetailsNCT07282067
Ankle Arthrodesis, Ankle Fusion
Phoenix, Arizona, United States
View Trial Details